<DOC>
	<DOCNO>NCT02960607</DOCNO>
	<brief_summary>The purpose study investigate whether high-dose icotinib treatment beyond disease progression beneficial NSCLC patient EGFR mutation respond EGFR TKI .</brief_summary>
	<brief_title>High-dose Icotinib Treatment Beyond Progression EGFR Mutant NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm stage IIIB/IV NSCLC Investigator confirm progression accord RECIST 1.1 previous icotinib treatment Patients whose tumor : EGFR mutationpositive T790M mutationnegative Performance status : WHO 02 Measurable disease accord RECIST 1.1 least one measureable lesion .if one measureable lesion , biological nature must confirm cytology histology single diameter lesion could measure least one follow method : Chest abdominal compute tomography ( CT ) magnetic resonance imaging ( MRI ) , conventional method diameter least 20mm diameter spiral CT OR least 10mm ANC ≥ 1.5*109/L , Platelets ≥ 75*109/L , Hgb≥ 9g/dL , Alanine amino transferase ≤ 2 × Upper limit normal ( ULN ) , Alkaline phosphatase ≤ 2.5 × ULN ( &lt; 5 × ULN liver metastasis ) , Serum Creatinine ≤ 1.5 × ULN Women childbearing age must pregnancy test 7 day treatment result negative , men childbearing age : surgical sterilization treatment end three month take contraceptive measure Patient must able comply protocol Patient symptomatic central nervous system metastases Patient know active hepatitis B C , HIV infection Pregnant breastfeeding . Patient uncontrolled undercurrent illness circumstance could limit compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>